Phase II study of raltitrexed ('Tomudex') for patients with advanced soft tissue sarcomas refractory to doxorubicin-containing regimens

Anti-Cancer Drugs

Volumn 10, Issue 10, 1999, Pages 873-877

  Blay, J Y ^a,c   Judson, I ^a   Rodenhuis, S ^a   Hermans, C ^a   Smith, M ^a   Van Glabbeke, M ^b   Verweij, J ^b  

^a EORTC DATA CENTER   (Belgium)

^b ASTRAZENECA   (United Kingdom)

^c CENTRE LÉON BÉRARD   (France)

Author keywords

Advanced soft tissue sarcoma; Chemotherapy; Doxorubicin; Drug resistance; EORTC; Ifosfamide; Phase II trial; Raltitrexed; Sarcoma; Tomudex

Indexed keywords

ANTHRACYCLINE ANTIBIOTIC AGENT; CHLORMETHINE DERIVATIVE; DOXORUBICIN; FOLIC ACID ANTAGONIST; IFOSFAMIDE; RALTITREXED;

ADULT; ADVANCED CANCER; AGED; ARTICLE; ASTHENIA; CANCER GROWTH; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEBRILE NEUTROPENIA; FEMALE; HEADACHE; HUMAN; LETHARGY; MALE; MULTICENTER STUDY; NAUSEA; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SOFT TISSUE SARCOMA; THROMBOCYTOPENIA;

EID: 0033383724     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001813-199911000-00002     Document Type: Article

References (27)

1. O'Bryan RM, Baker LH, Gottlieb JB, et al. Dose response evaluation of adriamycin in neoplasma. Cancer 1977; 39: 1940-8.
2. Santoro A, Tursz T, Mouridsen H, et al. Doxorubicin versus CyVADic versus ifosfamide plus doxorubicin in first line treatment of advanced soft tissue sarcomas. A randomized study of the EORTC Soft tissue and bone sarcoma group. J Clin Oncol 1995; 13: 1537-45.
3. Demetri GD, Elias AD. Results of single agents and combination chemotherapy for advanced soft tissue sarcomes. Hematol Oncol Clin N Am 1995; 9: 765-85.
4. Van Oosterom AT, Verweij J. New drugs for the treatment of sarcomas. Hematol Oncol Clin N Am 1995; 9: 909-25.
5. Cerny T, Leyvraz S, Daggi H, et al. Phase II trial of ifosfamide and mesna in advanced soft tissue sarcoma patients: a definite dose response relationship. Proc Am Soc Clin Oncol 1992; 11: 416 (abstr 1462).
6. Le Cesne A, Antoine E, Spielmann M, et al. High-dose Ifosfamide (HDI) without hematological support in 55 consecutive patients with advanced sarcomas: analysis of toxicities with a fractionated continuous infusion schedule. J Clin Oncol 1995; 13: 1600-8.
7. Nielsen OS, Judson I, van Hoesel Q, et al. High dose ifosfamide in advanced soft tissue sarcoma. A multicenter phase II study of the EORTC soft tissue and bone sarcoma group. Proc Am Soc Clin Oncol 1998; 17: 517a (abstr 1992).
8. Gottlieb JA, Benjamin RS, Baker LH. Role of DTIC (NSC-45338) in the chemotherapy of sarcomas. Cancer Treat Rep 1976; 60: 199-203.
9. Buesa JM, Mouridsen HT, Van Oosterom AT, et al. High dose DTIC in advanced soft-tissue sarcomas of the adult. A phase II study of the EORTC soft-tissue and bone-sarcoma group. Ann Oncol 1991; 2: 307-9.
10. Patel SR, Kaye A, Linke M, et al. Phase II study of paclitaxel in patients with soft tissue sarcoma. Sarcoma 1997; 1: 5-7.
11. Dombernovski P, Buesa J, Pinedo HM, et al. VP-16 in advanced soft tissue sarcoma: a phase II study of the EORTC soft tissue bone and sarcoma group. Eur J Cancer Clin Oncol 1987; 23: 579-83.
12. Budd GT, Metch B, Balcerzak SP, et al. High dose CDDP for metastatic soft tissue sarcomas. Cancer 1990; 65: 866-9.
13. Goldstein D, Cheuvart B, Trump DL, et al. Phase II trial of carboplatin in soft tissue sarcomas. Am J Clin Oncol 1990; 13: 420-3.
14. Hoesel QGCM, Verweij J, Catimel G, et al. Phase II study with docetaxel (Taxotere) in advanced soft tissue sarcoma of the adult. Ann Oncol 1994; 5: 539-43.
15. Bramwell V, Blackstein M, Belanger K, et al. A phase II study of docetaxel in chemotherapy naive patients with recurrent or metastatic adult soft tissue sarcoma. Sarcoma 1998; 2: 29-34.
16. Verweij J, Judson I, Crowther D, et al. Randomized study comparing docetaxel with doxorubicin in previously untreated soft tissue sarcomas. Proc Am Soc Clin Oncol 1997; 16: 496a (abstr 1788).
17. Waltzman R, Schwartz GK, Shorter S, et al. Lack of efficacy of paclitaxel in patients with advanced soft tissue sarcoma. Proc Am Soc Clin Oncol 1996; 15: 526 (abstr 1699).
18. Keizer J, Crowther D, Nielsen OS, et al. EORTC group phase II study of oral etoposide for pretreated soft tissue sarcoma. Sarcoma 1997; 1: 99-101.
19. Bramwell VHC, Eisenhauer EA, Blackstein M, et al. Phase II study of topotecan in patients with recurrent or metastatic soft tissue sarcoma. Ann Oncol 1995; 6: 847-9.
20. Fidias P, Demetri G, Harmon DC, et al. Navelbine shows activity in previously treated sarcoma patients: phase II results from MGH/Dana Farber/Partner Cancer care study. Proc Am Soc Clin Oncol 1998; 17: 513a (abstr 1977).
21. Späth-Schwalbe E, Koschüth A, Grünewald R. Gemcitabine in pretreated patients with advanced soft tissue sarcomas. Preliminary results from a phase II trial. Proc Am Soc Clin Oncol 1998; 17: 513a (abstr 1976).
22. Rustum YM, Harstrick A, Cao S, et al. Thymidylate synthase inhibitors in cancer therapy: direct and indirect inhibitors. J Clin Oncol 1997: 15: 389-400.
23. Cunningham D. Mature results from three large controlled studies with raltitrexed ('Tomudex'). Br J Cancer 1998; 77 (suppl 2): 15-21.
24. Judson IR. Tomudex (raltitrexed) development: preclinical, phase I and II studies. Anti-Cancer Drugs 1997; 8 (suppl 2): S5-9.
25. Simon R. Optimal two stage designs for phase II clinical trials. Control Clin Trials 1989; 10: 1-10.
26. Edmonson JH, Ryan LM, Blum RG, et al. Randomized comparison of doxorubicin alone versus ifosfamide plus doxorubicin or mitomycin, doxorubicin and cisplatin against advanced soft tissue sarcomas. J Clin Oncol 1993; 11: 269-75.
27. Antman KH, Crowley J, Balcerzak SP, et al. An intergroup phase III randomized study of doxorubicin and dacarbazine with or without ifosfamide an Mesna in advanced soft tissue and bone sarcomas. J Clin Oncol 1993; 7: 1276-85.